SCHEMBL5485308

SCHEMBL5485308

COc1cc2ncnc(Nc3cccc(C(C)=O)c3)c2cc1OC

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 10/20 0.77
MAPK14 Q16539 4/20 0.77
KDR P35968 6/20 0.71
RET P07949 4/20 0.71
EPHB2 P29323 2/20 0.71
FGFR1 P11362 1/20 0.71
FLT1 P17948 1/20 0.71
CDK2 P24941 1/20 0.71
PIK3R1 P27986 1/20 0.71
KIF5B P33176 1/20 0.71
TTBK1 Q5TCY1 1/20 0.71
SRC P12931 4/20 0.70
NOD1 Q9Y239 1/20 0.69
ABCG2 Q9UNQ0 3/20 0.68
ABCB1 P08183 2/20 0.68
KDM4E B2RXH2 3/20 0.67
MAPT P10636 3/20 0.67
MAPK1 P28482 3/20 0.67
ABL1 P00519 2/20 0.67
CYP1A2 P05177 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5471735 0.99 EGFR (0.75) EGFRMAPK14KDRRETEPHB2
SCHEMBL3238919 0.95 EGFR (0.70) EGFRMAPK14KDRRETEPHB2
Hydrochloric Acid SCHEMBL3238911 0.94 EGFR (0.68) EGFRMAPK14KDRRETEPHB2
SCHEMBL3239025 0.92 EGFR (0.66) EGFRMAPK14KDRRETEPHB2
SCHEMBL17940152 0.91 EGFR (0.70) EGFRMAPK14KDRRETEPHB2
SCHEMBL5569012 0.90 EGFR (0.72) EGFRMAPK14KDRRETEPHB2
SCHEMBL3239473 0.88 EGFR (0.65) EGFRMAPK14KDRRETEPHB2
SCHEMBL6786328 0.88 EGFR (0.77) EGFRMAPK14KDRRETEPHB2
Hydrochloric Acid SCHEMBL7093945 0.88 EGFR (0.69) EGFRMAPK14MAPTFBP1ERBB2
SCHEMBL17940143 0.88 EGFR (0.74) EGFRMAPK14KDRRETEPHB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513267-B2 4-anilinoquinazoline derivatives with adenosine-kinase inhibitor properties UNIVERSIDADE ESTADUAL DE CAMPINAS-UNICAMP (BR) 2013-08-20 US disclosed
EP-1737832-B1 4-ANILINOQUINAZOLINE DERIVATIVES WITH ADENOSINE-KINASE INHIBITORY PROPERTIES UNICAMP (BR) 2011-12-14 EP disclosed
US-20070060600-A1 4-Anilinequinazolines with adenosine-kiase inhibitor properties UNIVERSIDADE ESTADUAL DE CAMPINAS-UNICAMP (BR) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060600-A1 4-Anilinequinazolines with adenosine-kiase inhibitor properties ADK, AK1, ADORA3 EGFR 3142/4885MAPK14 984/4885KDR 1289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.